Pandemic Preparedness Diagnostics Market is expected to reach USD 5.5 billion by 2031

Pandemic Preparedness Diagnostics Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the pandemic preparedness diagnostics market will expand from USD 4.3 billion in 2026 to USD 5.5 billion in 2031 at a CAGR of 5.0% during the forecast period.

Pandemic Preparedness Diagnostics refers to those diagnostic technologies or surveillance systems that are designed to provide health care providers and their public health systems the necessary technology and means to quickly identify, monitor, and contain emerging infectious disease threats before they spread on a large scale. Technologies that fall within this category include: multiplex PCR analyses, next-generation sequencing machine platforms, point-of-care diagnostic methods, and surveillance systems for pathogen detection that have been integrated into the public health network. On June 2025, the U.S. Government Accountability Office (GAO) focused on the fact that pandemics (ex. avian influenza) need a well defined national and coordinated strategy for a national diagnostic testing method along with public and private sector involvement and cooperation to execute. WHO’s 2025 pandemic preparedness framework also called attention to the necessity of developing functional diagnostic capacity inside of the systems to monitor for pandemic outbreaks, provide clinical care, and respond to and deploy countermeasure systems to manage and contain emerging pandemic threats. The global push for investing into “100 Days Mission” to enhance response to outbreak scenarios continues to be a major contributor to the current growth in investments for scalable diagnostic preparedness infrastructure.

Request a free sample copy or view the report summary: Pandemic Preparedness Diagnostics Market Report

Pandemic Preparedness Diagnostics Market Report Highlights

• WHO launched a US$15 million regional initiative in 2025 to strengthen collaborative surveillance and pandemic diagnostic readiness.

• WHO’s 2025 preparedness framework identified diagnostics among the primary pillars of respiratory pandemic resilience and emergency response.

• CDC expanded clinical laboratory data integration across more than 200 reportable infectious disease conditions during 2025.

• WHO listed emergency-use mpox diagnostic products from 10 manufacturers during 2025 regulatory preparedness initiatives

Pandemic Preparedness Diagnostics Market Growth Drivers and Restraints

Growth Drivers:

• The diverse and coordinated investments made by government agencies and international organizations in diagnostic-readiness will significantly enhance the growth of the diagnostics market. In January 2025, the WHO, FAO, UNICEF and the World Bank launched a three-year preparedness initiative to improve surveillance systems, diagnostic capacity and environmental monitoring within South-East Asia with development funding of over $15 million from the Pandemic Fund. The initiative aims to strengthen early warning systems and develop rapid pathogen detection methods prior to large-scale transmission of a given pathogen. The WHO will identify diagnostics as a priority area for response capabilities; this designation will put diagnostics on an equal basis with emergency coordination and countermeasure deployment. The sustained increase in direct government funding for both decentralized testing, molecular surveillance and integrated laboratory infrastructure supports continued growth of worldwide demand for pandemic preparedness diagnostic technologies.

• The expansion of molecular diagnostics and rapid multiplex testing systems is another major driver of the diagnostics market. In April 2025, the CDC announced an expansion of access to clinical laboratory data through new contracts with various laboratory companies. This expansion will significantly increase the ability to monitor infectious diseases in real-time across over 200 reportable conditions.Moreover, WHO's analysis of the global landscape of in vitro diagnostics in October 2025, determined that advanced in vitro diagnostics capable of identifying both bacteria with priority pathogens and antibiotic-resistance genes, are increasingly being produced via scalable molecular analysis. Finally, the International Pandemic Preparedness Secretariat's 2026 implementation report highlighted timely development pipelines and improved diagnostic coordination as key priorities for meeting global missions of "100 days" response. In summary, all of these initiatives are contributing to increased adoption of multiplex PCR systems, sequencing technologies and artificial intelligence-based pathogen surveillance platforms.

Restraints:

• Despite increased investment, fragmented global coordination, inconsistent regulatory frameworks, and limited equitable access to diagnostics remain major barriers. The 2025 GAO assessment reported that the U.S. still lacks a fully coordinated national strategy for pandemic diagnostic testing preparedness, limiting rapid response efficiency during emerging outbreaks.

Pandemic Preparedness Diagnostics Market Key Development

• June 2025: bioM?©rieux strengthened its antimicrobial resistance diagnostics capabilities by acquiring assets from Day Zero Diagnostics, a company specialising in genome sequencing and machine learning-based infectious disease detection. This acquisition enables faster identification of pathogens and their antibiotic resistance profiles directly from blood samples, significantly reducing diagnostic time from days to hours.

• January 2026 – Thermo Fisher Scientific expanded automated molecular diagnostic systems supporting high-throughput syndromic testing for respiratory and bloodstream infections, improving turnaround time and hospital laboratory workflow efficiency.

• February 2026 – Roche Diagnostics advanced cobas multiplex respiratory syndromic testing portfolio, enhancing simultaneous detection of multiple viral pathogens in hospital-based molecular diagnostic workflows.

Pandemic Preparedness Diagnostics Market Segmentation

Knowledge Sourcing Intelligence has segmented the Syndromic Infectious Disease Diagnostics Market Growth based on product type, technology, application, and geography:

Pandemic Preparedness Diagnostics Market By Product Type

• Test Kits

• Instruments

• Software & Services

Pandemic Preparedness Diagnostics Market By Technology

• Polymerase Chain Reaction (PCR)

• Isothermal Nucleic Acid Amplification

• Next-Generation Sequencing (NGS)

• Immunoassays

Pandemic Preparedness Diagnostics Market By Application

• Disease Surveillance

• Outbreak Detection

• Emergency Diagnostics

• Screening & Monitoring

Pandemic Preparedness Diagnostics Market By Geography

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Indonesia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Pandemic Preparedness Diagnostics Market Key Players

• Thermo Fisher Scientific

• Roche Diagnostics

• Abbott Laboratories

• Danaher Corporation

• bioMérieux

• QIAGEN

• Hologic

• BD (Becton, Dickinson and Company)

• Cepheid

• Seegene